Shares of Establishment Labs Holdings Inc. (ESTA) surged 8.01% in pre-market trading on Thursday, following the company's impressive fourth-quarter earnings report and positive outlook for its entry into the US market.
The medical device company reported a robust start in the US, generating $3.3 million in sales in the first two months of the launch, exceeding initial expectations. This strong performance, coupled with a 41% increase in total revenue for Q4 to $44.5 million driven by higher production volumes and early US sales, has bolstered investor confidence.
Furthermore, Establishment Labs has successfully onboarded over 650 accounts in the US market, with 450 placing orders and an impressive 88% reordering rate, indicating strong product acceptance. The company is on track to achieve its first positive EBITDA quarter in 2025, supported by gross margin expansion and operational efficiency improvements.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。